ITRM — Iterum Therapeutics Balance Sheet
0.000.00%
- $30.11m
- $49.64m
Annual balance sheet for Iterum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.9 | 81.4 | 60.8 | 23.9 | 24.1 |
| Net Total Receivables | 0.865 | 1.21 | 0.513 | 0.233 | 0.066 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 21.5 | 83.3 | 62.4 | 25.6 | 24.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.68 | 3.83 | 1.84 | 0.6 | 0.023 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 32.8 | 91.5 | 66.8 | 26.3 | 44.6 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 41.7 | 12.9 | 9.06 | 13.5 | 17.6 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 83.4 | 41.3 | 38.8 | 32.7 | 48.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -50.6 | 50.2 | 28 | -6.4 | -4.08 |
| Total Liabilities & Shareholders' Equity | 32.8 | 91.5 | 66.8 | 26.3 | 44.6 |
| Total Common Shares Outstanding |